Boehringer offloads an mTOR cancer drug as Xynomic plots a quick advance in the clinic
As Boehringer Ingelheim marches on with a €20 billion R&D game plan to get 15 more drugs approved in the next 7 years, it’s shedding another early-stage oncology asset for some cash.
Xynomic Pharma is committing up to $800 million for an mTORC1/2 inhibitor in the licensing deal — its second with the German pharma — but didn’t break out the upfront, milestones and potential royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
